SEC Filings - Aerovate Therapeutics, Inc.

Filing date	Form	Description	View
April 19, 2023	ARS	An annual report to security holders	0001798749-23-000026.pdf 0001798749-23-000026.rtf View HTML
March 30, 2022	10-K	Annual report which provides a comprehensive overview of the company for the past year	0001493152-22-008189.pdf 0001493152-22-008189.rtf 0001493152-22-008189.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
March 29, 2023	10-K	Annual report which provides a comprehensive overview of the company for the past year	0001798749-23-000015.pdf 0001798749-23-000015.rtf 0001798749-23-000015.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
June 24, 2021	CORRESP	CORRESP	0001104659-21-084801.pdf 0001104659-21-084801.rtf 0001104659-21-084801.xls View HTML
June 25, 2021	CORRESP	CORRESP	0001104659-21-085700.pdf 0001104659-21-085700.rtf 0001104659-21-085700.xls View HTML
June 25, 2021	CORRESP	CORRESP	0001104659-21-085705.pdf 0001104659-21-085705.rtf 0001104659-21-085705.xls View HTML
June 9, 2021	CORRESP	CORRESP	0001104659-21-078874.pdf 0001104659-21-078874.rtf 0001104659-21-078874.xls View HTML
August 19, 2022	CORRESP	CORRESP	0001493152-22-023616.pdf 0001493152-22-023616.rtf 0001493152-22-023616.xls View HTML
May 6, 2021	DRS	Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy	0001104659-21-062408.pdf 0001104659-21-062408.rtf 0001104659-21-062408.xls View HTML
June 29, 2021	EFFECT	EFFECT	9999999995-21-002582.pdf 9999999995-21-002582.rtf 9999999995-21-002582.xls View HTML

Data provided by Kaleidoscope.